---
title: "Symptomatic treatment for Alzheimer disease: evidence for current therapies and future directions"
id: "nature-reviews-neurology-1-symptomatic-treatment-for-alzheimer-disease-current-evidence-and-future"
canonical_url: "https://medichelpline.com/clinical-feed/nature-reviews-neurology-1-symptomatic-treatment-for-alzheimer-disease-current-evidence-and-future"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "Nature Reviews Neurology"
source_url: "https://www.nature.com/articles/s41582-026-01260-5"
published_at: "2026-09-01T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Symptomatic treatment for Alzheimer disease: evidence for current therapies and future directions
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-reviews-neurology-1-symptomatic-treatment-for-alzheimer-disease-current-evidence-and-future
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** Nature Reviews Neurology
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41582-026-01260-5)
- **Published At:** 2026-09-01T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Symptomatic therapies remain a central component of care for **Alzheimer disease (AD)**, providing immediate benefits for cognition, activities of daily living and behavioural symptoms even as disease-modifying treatments are developed. - **Non-pharmacological interventions** — including cognitive training, cognitive stimulation therapy, structured physical exercise and multimodal lifestyle programmes — show consistent small-to-moderate benefits, particularly in individuals with mild cognitive impairment, but scalability and real-world implementation are barriers. - Established drugs (notably **cholinesterase inhibitors** and **memantine**) yield modest but clinically meaningful effects; biomarker-stratified analyses suggest greater benefit when AD pathology is confirmed. - Emerging symptomatic strategies target alternative pathways and mechanisms (muscarinic, σ1, serotonergic, neurotrophic), with multitarget agents and repurposed drugs offering potential to broaden symptomatic benefit beyond classic cholinergic and glutamatergic approaches. - **Neuropsychiatric symptoms** are common and cause high burden; personalised psychosocial interventions reduce agitation and depression meaningfully, while atypical antipsychotics show only modest efficacy with important safety concerns. - Newer pharmacological agents for behavioural symptoms (for example, brexpiprazole for agitation and pimavanserin for psychosis) show promise with potentially improved safety profiles, but effect sizes and safety require careful interpretation. - Future progress depends on **biomarker-informed** patient selection, incorporation of circuit-level measures, rational combination strategies that integrate pharmacological and non-pharmacological modalities, and prioritisation of patient-centred outcomes. - Symptomatic treatments will continue to be essential to improve quality of life for people living with AD even as disease-targeted therapies change long-term trajectories.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41582-026-01260-5#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Reviews Neurology](https://media.springernature.com/full/nature-cms/uploads/product/nrneurol/header-0e3b6e66371daa4e48420b30ea763bd4.svg) ](https://www.nature.com/nrneurol) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41582-026-01260-5) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nrneurol/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nrneurol/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nrneurol/news-and-comment) * [ Current issue ](https://www.nature.com/nrneurol/current-issue) * [ Collections ](https://www.nature.com/nrneurol/collections) * [Follow us on Facebook ](https://www.facebook.com/NatureReviews) * [Follow us on X ](https://twitter.com/NatRevNeurol) * [ Subscribe ](https://www.nature.com/nrneurol/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41582) * [ RSS feed ](https://www.nature.com/nrneurol.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nrneurol/aims) * [ Journal Information ](https://www.nature.com/nrneurol/journal-information) * [ Editorial policies ](https://www.nature.com/nrneurol/editorial-policies) * [ About the Editors ](https://www.nature.com/nrneurol/editors) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nrneurol/reviews-cross-journal-editorial-team) * [ Journal Credits ](https://www.nature.com/nrneurol/journal-credits) * [ Editorial input and checks ](https://www.nature.com/nrneurol/editorial-input-and-checks) * [ Editorial Values Statement ](https://www.nature.com/nrneurol/editorial-values-statement) * [ Journal Metrics ](https://www.nature.com/nrneurol/journal-impact) * [ Publishing model ](https://www.nature.com/nrneurol/publishing-model) * [ Web Feeds ](https://www.nature.com/nrneurol/web-feeds) * [ Contact ](https://www.nature.com/nrneurol/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors ](https://www.nature.com/nrneurol/for-authors) * [ For Referees ](https://www.nature.com/nrneurol/for-referees) * [Submit manuscript ](https://mts-nrneurol.nature.com/cgi-bin/main.plex) * [ Subscribe ](https://www.nature.com/nrneurol/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41582) * [ RSS feed ](https://www.nature.com/nrneurol.rss) 1. [nature](https://www.nature.com/) 2. [nature reviews neurology](https://www.nature.com/nrneurol) 3. [review articles](https://www.nature.com/nrneurol/articles?type=review-article) 4. article * Review Article * Published: 01 September 2026 # Symptomatic treatment for Alzheimer disease: current evidence and future directions * [Clive Ballard](https://www.nature.com/articles/s41582-026-01260-5#auth-Clive-Ballard-Aff1) [ORCID: orcid.org/0000-0003-0022-5632](https://orcid.org/0000-0003-0022-5632)[1](https://www.nature.com/articles/s41582-026-01260-5#Aff1), * [Pat Doherty](https://www.nature.com/articles/s41582-026-01260-5#auth-Pat-Doherty-Aff2)[2](https://www.nature.com/articles/s41582-026-01260-5#Aff2), * [Zahinoor Ismail](https://www.nature.com/articles/s41582-026-01260-5#auth-Zahinoor-Ismail-Aff3-Aff4-Aff5-Aff6-Aff7) [ORCID: orcid.org/0000-0002-5529-3731](https://orcid.org/0000-0002-5529-3731)[3](https://www.nature.com/articles/s41582-026-01260-5#Aff3),[4](https://www.nature.com/articles/s41582-026-01260-5#Aff4),[5](https://www.nature.com/articles/s41582-026-01260-5#Aff5),[6](https://www.nature.com/articles/s41582-026-01260-5#Aff6),[7](https://www.nature.com/articles/s41582-026-01260-5#Aff7), * [Anne Corbett](https://www.nature.com/articles/s41582-026-01260-5#auth-Anne-Corbett-Aff8)[8](https://www.nature.com/articles/s41582-026-01260-5#Aff8) & * … * [Jeffrey L. Cummings](https://www.nature.com/articles/s41582-026-01260-5#auth-Jeffrey_L_-Cummings-Aff9)[9](https://www.nature.com/articles/s41582-026-01260-5#Aff9) Show authors [_Nature Reviews Neurology_](https://www.nature.com/nrneurol) (2026) [Cite this article](https://www.nature.com/articles/s41582-026-01260-5#citeas) [ Save article ](https://www.nature.com/articles/s41582-026-01260-5/save-research?_csrf=rR_ThtIi4K9nDpTBjF2tgqYyfAZRjsUZ) [ View saved research ](https://www.nature.com/saved-research) ## Abstract Symptomatic treatment remains central to the clinical management of Alzheimer disease (AD), even as disease-targeted therapies emerge. This Review synthesizes current evidence for pharmacological and non-pharmacological symptomatic therapies targeting cognition, function and neuropsychiatric symptoms in AD. Non-pharmacological interventions, including cognitive training, physical exercise, cognitive stimulation therapy and multimodal lifestyle programmes, show small-to-moderate benefits, particularly in mild cognitive impairment, although implementation challenges persist. Established pharmacological treatments, notably cholinesterase inhibitors and memantine, deliver modest but significant benefits, with biomarker-stratified analyses suggesting the greatest benefit in individuals with confirmed AD pathology. Advances in muscarinic agonists, multitarget agents, neurotrophic modulators and repurposed drugs highlight emerging opportunities for broader symptomatic benefit. Neuropsychiatric symptoms remain highly prevalent and burdensome; personalized psychosocial interventions demonstrate meaningful reductions in agitation and depression, whereas atypical antipsychotics offer only modest efficacy with substantial safety concerns. Newer agents, including brexpiprazole for agitation and pimavanserin for psychosis, show promise but require careful interpretation of effect size and safety. Future progress will depend on biomarker-informed patient selection, integration of circuit-level measures, rational combination strategies spanning pharmacological and non-pharmacological modalities, and adoption of patient-centred outcomes. Symptomatic therapies will remain essential for improving quality of life in people with AD, even as disease-targeted therapies reshape disease trajectories. ## Key points * Symptomatic therapies remain central to Alzheimer disease care, providing immediate cognitive, functional and behavioural benefits. * Non-pharmacological interventions show consistent but modest efficacy, with the strongest evidence for cognitive training, structured physical exercise and multimodal lifestyle programmes; however, scalability and real-world implementation remain major barriers to clinical impact. * Established pharmacological treatments deliver modest yet clinically meaningful benefit, with emerging biomarker-stratified data suggesting greater responsiveness in individuals with confirmed Alzheimer disease pathology and underscoring the need for precision symptomatic therapeutics. * Next-generation symptomatic agents targeting muscarinic, σ1, serotonergic and neurotrophic pathways are advancing, offering opportunities for broader neurotransmitter and circuit-level modulation beyond traditional cholinergic and glutamatergic mechanisms. * Neuropsychiatric symptoms demand tailored, mechanism-informed approaches: personalized psychosocial interventions yield meaningful improvements, whereas newer agents such as brexpiprazole and pimavanserin offer incremental but promising efficacy with more favourable safety considerations than previously used atypical antipsychotics. * Future progress will rely on integrated, biomarker-guided combination strategies, incorporating pharmacological and non-pharmacological modalities and prioritizing patient-centred outcomes to optimize symptomatic benefit alongside disease modification. This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41582-026-01260-5) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41582-026-01260-5) Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 € / 30 days cancel any time [Learn more](https://shop.nature.com/products/plus/?region=ROW) Subscribe to this journal Receive 12 print issues and online access 176,64 € per year only 14,72 € per issue [Learn more](https://www.nature.com/nrneurol/subscribe) Buy this article * Purchase on SpringerLink * Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/authorize/natureuser?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41582-026-01260-5) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) ### Explore related subjects Discover the latest articles and news in related subjects. * [Alzheimer's disease](https://www.nature.com/subjects/alzheimers-disease) * [Cognitive ageing](https://www.nature.com/subjects/cognitive-ageing) ## References 1. Cummings, J., Lanctot, K., Grossberg, G. & Ballard, C. Progress in pharmacologic management of neuropsychiatric syndromes in neurodegenerative disorders: a review. _JAMA Neurol._ (2024). [Article](https://doi.org/10.1001%2Fjamaneurol.2024.0586) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38558015) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11164642) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Progress%20in%20pharmacologic%20management%20of%20neuropsychiatric%20syndromes%20in%20neurodegenerative%20disorders%3A%20a%20review&journal=JAMA%20Neurol.&doi=10.1001%2Fjamaneurol.2024.0586&publication_year=2024&author=Cummings%2CJ&author=Lanctot%2CK&author=Grossberg%2CG&author=Ballard%2CC) 2. Cummings J. L. et al. Alzheimer’s disease drug development pipeline: 2025. _Alzheimers Dement._ **11** , e70098 (2025); [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Alzheimer%E2%80%99s%20disease%20drug%20development%20pipeline%3A%202025&journal=Alzheimers%20Dement.&volume=11&publication_year=2025&author=Cummings%2CJL) 3. Perneczky, R., Dom, G., Chan, A., Falkai, P. & Bassetti, C. Anti-amyloid antibody treatments for Alzheimer’s disease. _Eur. J. Neurol._ (2024). [Article](https://doi.org/10.1111%2Fene.16049) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37697714) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Anti-amyloid%20antibody%20treatments%20for%20Alzheimer%E2%80%99s%20disease&journal=Eur.%20J.%20Neurol.&doi=10.1111%2Fene.16049&publication_year=2024&author=Perneczky%2CR&author=Dom%2CG&author=Chan%2CA&author=Falkai%2CP&author=Bassetti%2CC) 4. Baker, L. D. et al. Structured vs self-guided multidomain lifestyle interventions for global cognitive function: the US POINTER randomized clinical trial. _JAMA_ (2024). [Article](https://doi.org/10.1001%2Fjama.2025.12923) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=39454050) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11669049) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Structured%20vs%20self-guided%20multidomain%20lifestyle%20interventions%20for%20global%20cognitive%20function%3A%20the%20US%20POINTER%20randomized%20clinical%20trial&journal=JAMA&doi=10.1001%2Fjama.2025.12923&publication_year=2024&author=Baker%2CLD) 5. Lee, D., Clark, E. D., Antonsdottir, I. M. & Porsteinsson, A. P. Brexpiprazole for agitation associated with dementia due to Alzheimer’s disease. _J. Am. Med. Dir. Assoc._ (2024). [Article](https://doi.org/10.1016%2Fj.jamda.2024.105173) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=39689865) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368643) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Brexpiprazole%20for%20agitation%20associated%20with%20dementia%20due%20to%20Alzheimer%E2%80%99s%20disease&journal=J.%20Am.%20Med.%20Dir.%20Assoc.&doi=10.1016%2Fj.jamda.2024.105173&publication_year=2024&author=Lee%2CD&author=Clark%2CED&author=Antonsdottir%2CIM&author=Porsteinsson%2CAP) 6. Ballard, C., Sultana, J., Doherty, P., Williams, G. & Corbett, A. Identifying synergistic combinations of repurposed treatments for Alzheimer’s disease. _J. Prev. Alzheimers Dis._ **12** , 100329 (2025). [Article](https://doi.org/10.1016%2Fj.tjpad.2025.100329) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=41145339) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12627884) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Identifying%20synergistic%20combinations%20of%20repurposed%20treatments%20for%20Alzheimer%E2%80%99s%20disease&journal=J.%20Prev.%20Alzheimers%20Dis.&doi=10.1016%2Fj.tjpad.2025.100329&volume=12&publication_year=2025&author=Ballard%2CC&author=Sultana%2CJ&author=Doherty%2CP&author=Williams%2CG&author=Corbett%2CA) 7. Blanco-Silvente, L. et al. Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer’s disease: a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16,106 patients. _Int. J. Neuropsychopharmacol._ **20** , 519–528 (2017). [Article](https://doi.org/10.1093%2Fijnp%2Fpyx012) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXitVOjs7fO) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28201726) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5492783) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Discontinuation%2C%20efficacy%2C%20and%20safety%20of%20cholinesterase%20inhibitors%20for%20Alzheimer%E2%80%99s%20disease%3A%20a%20meta-analysis%20and%20meta-regression%20of%2043%20randomized%20clinical%20trials%20enrolling%2016%2C106%20patients&journal=Int.%20J.%20Neuropsychopharmacol.&doi=10.1093%2Fijnp%2Fpyx012&volume=20&pages=519-528&publication_year=2017&author=Blanco-Silvente%2CL) 8. Mielke, M. M. et al. Recommendations for clinical implementation of blood-based biomarkers for Alzheimer’s disease. _Alzheimers Dement._ (2024). [Article](https://doi.org/10.1002%2Falz.14184) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=39711285) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226247) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Recommendations%20for%20clinical%20implementation%20of%20blood-based%20biomarkers%20for%20Alzheimer%E2%80%99s%20disease&journal=Alzheimers%20Dement.&doi=10.1002%2Falz.14184&publication_year=2024&author=Mielke%2CMM) 9. Gates, N. J., Sachdev, P. S., Fiatarone Singh, M. A. & Valenzuela, M. Cognitive and memory training in adults at risk of dementia: a systematic review. _BMC Geriatr._ **11** , 55 (2011). [Article](https://link.springer.com/doi/10.1186/1471-2318-11-55) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21942932) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191477) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cognitive%20and%20memory%20training%20in%20adults%20at%20risk%20of%20dementia%3A%20a%20systematic%20review&journal=BMC%20Geriatr.&doi=10.1186%2F1471-2318-11-55&volume=11&publication_year=2011&author=Gates%2CNJ&author=Sachdev%2CPS&author=Fiatarone%20Singh%2CMA&author=Valenzuela%2CM) 10. Zhang, H. et al. Effect of computerised cognitive training on cognitive outcomes in mild cognitive impairment: a systematic review and meta-analysis. _BMJ Open_ **9** , e027062 (2019). [Article](https://doi.org/10.1136%2Fbmjopen-2018-027062) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31427316) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701629) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Effect%20of%20computerised%20cognitive%20training%20on%20cognitive%20outcomes%20in%20mild%20cognitive%20impairment%3A%20a%20systematic%20review%20and%20meta-analysis&journal=BMJ%20Open&doi=10.1136%2Fbmjopen-2018-027062&volume=9&publication_year=2019&author=Zhang%2CH) 11. Sahaf, S., Salimi, Z. & Bidaki, R. Non-pharmacological interventions targeting working memory in mild cognitive impairment: a systematic review and meta-analysis. _Adv. Rehabil._ **39** , 46–62 (2025). [Article](https://doi.org/10.5114%2Fareh.2025.149343) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Non-pharmacological%20interventions%20targeting%20working%20memory%20in%20mild%20cognitive%20impairment%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Adv.%20Rehabil.&doi=10.5114%2Fareh.2025.149343&volume=39&pages=46-62&publication_year=2025&author=Sahaf%2CS&author=Salimi%2CZ&author=Bidaki%2CR) 12. Li, R., Geng, J., Yang, R., Ge, Y. & Hesketh, T. Effectiveness of computerized cognitive training in delaying cognitive function decline in people with mild cognitive impairment: systematic review and meta-analysis. _J. Med. Internet Res._ **24** , e38624 (2022). [Article](https://doi.org/10.2196%2F38624) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=36301590) [P
## Related Clinical Research

- [Antihypertensive Drug Class and Risk of Incident Alzheimer’s Disease and Related Dementias: Replic](https://medichelpline.com/clinical-feed/medrxiv-17-antihypertensive-medication-class-and-incident-alzheimers-disease-and-related.md)
- [Late-life Learning and Cognitive Aging in Beirut: Design and Baseline of the 3LC Longitudinal Coho](https://medichelpline.com/clinical-feed/medrxiv-14-late-life-learning-cognition-and-aging-a-longitudinal-study-of-middle-and-older.md)
- [Carbon monoxide exposure may explain lower Parkinson's risk linked to smoking](https://medichelpline.com/clinical-feed/medical-news-today-0-why-smokers-may-have-a-lower-parkinson-s-risk-it-s-not-the-nicotine.md)
- [2026 Stroke Rehabilitation Guideline: Start Early and Address Physical, Cognitive, and Mental Heal](https://medichelpline.com/clinical-feed/medical-news-today-0-stroke-rehab-guidelines-emphasize-early-support-for-physical-cognitive-and.md)
- [Prevalence of cognitive impairment in older Palestinian adults in community and nursing homes](https://medichelpline.com/clinical-feed/plos-one-16-prevalence-of-cognitive-impairment-among-older-adult-palestinians-in-community.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.